Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2024/10/075592
CTRI/2024/10/075592
Not yet recruiting
Phase 2

A clinical study to evaluate the efficacy of combined effect of Vrikkamaya Ghan Vati (kalpita yoga) with Arka Punarnava in the management of Mutraghata w.s.r.to Chronic Kidney Disease

Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University Jodhpur1 site in 1 country60 target enrollmentStarted: November 5, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University Jodhpur
Enrollment
60
Locations
1
Primary Endpoint
Relief in sign and symptoms of Mutraghata
OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

It is a Randomized, Prospective, Open label, Interventional single arm clinical trial. Total 60 patients will be selected as per inclusion and exclusion criteria for the study. All the participants will receive Vrikkamaya Ghan Vati (Kalpita or Hypothetical coumpound) and Arka Punarnava . Dosage of Vrikkamaya Ghan Vati will be 1gm TDS and Arka Punarnava will be 20ml TDS. Total duration of the intervention will be 3 months and follow up will be 2 months after the completion of treatment

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
20.00 Year(s) to 70.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •Patients will be taken with symptoms of any kind of Mutraghata are present
  • •Glomerular filtration rate level.
  • •more than 30ml/min.
  • •Blood urea less than 150 mg/dl
  • •Serum creatinine level less than 5 mg/dl.

Exclusion Criteria

  • •Glomerular filtration rate level.
  • •less than 30ml/min.
  • •Blood urea more than 150 mg/dl
  • •Serum creatinine level more than 5 mg/dl
  • •Patients on dialysis treatment and other serious illness cardiovascular disease, Acute mental disorders, Acute organic diseases etc.

Outcomes

Primary Outcomes

Relief in sign and symptoms of Mutraghata

Time Frame: At baseline 4 weeks 8 weeks & 12 weeks

Secondary Outcomes

  • To asses the changes in all subjective and objective parameters of the study(3 months)

Investigators

Sponsor
Dr Sarvepalli Radhakrishnan Rajasthan Ayurved University Jodhpur
Sponsor Class
Research institution and hospital
Responsible Party
Principal Investigator
Principal Investigator

Dr BRAHMANAND SHARMA

University college of Ayurveda, Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Phase 1
Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer
NCT07392541Tongji Hospital29
Not yet recruiting
Not Applicable
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
NCT07309276Shanghai Junshi Bioscience Co., Ltd.864
Completed
Phase 2/3
Clinical study on Vimosa Softgel in vaginal dryness and vaginal prolapse
CTRI/2024/05/067423Abhinav Health Care Products Pvt Ltd72
Recruiting
Phase 2
Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients with steroid-refractory chronic Graft-versus-Host-Disease (SR-cGvHD) - RUX-ECP
2023-507754-33-00Medical Center - University Of Freiburg40
Not yet recruiting
Not Applicable
A clinical trial to study the effects of a novel combination pimple patch versus conventional topical gel in acne patients.
CTRI/2025/02/080180Dr Prathambigai S S50